ARCHIVES

NCI declined to pay for economic, quality of life analysis in Avastin, Erbitux study.

This article is from The Cancer Letter archive.

Vol. 31 No. 22 | June 3, 2005

Download PDF Visit The Full Archive

Related Articles

FDA Asks Advisory Group To Define Role Of Single-Arm Studies In Four Applications

September 4, 2009

NCI Closes Iressa Trial For NSCLC When Data Indicate No Survival Benefit

April 29, 2005

In Brief: Justice Department Files Civil Suit To recover $25 Billion From Tobacco

September 24, 1999

NCI Cooperative Group, Cancer Center Trials Listed

September 30, 2005

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

February 26, 2010

More RFPs For Smoking/Health Projects Planned For Release As Subcontracts For Enviro Control

March 14, 1975